(0.17%) 5 108.58 points
(0.18%) 38 308 points
(0.18%) 15 956 points
(-1.41%) $82.67
(4.42%) $2.01
(0.04%) $2 348.20
(-0.01%) $27.53
(3.87%) $957.75
(-0.18%) $0.933
(-0.25%) $11.00
(-0.46%) $0.797
(1.73%) $93.46
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 11.83%
@ $29.86
发出时间: 11 Mar 2024 @ 23:11
回报率: -26.33%
上一信号: Mar 11 - 21:31
上一信号:
回报率: -1.35 %
Live Chart Being Loaded With Signals
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency...
Stats | |
---|---|
今日成交量 | 469 008 |
平均成交量 | 1.54M |
市值 | 2.12B |
EPS | $0 ( 2024-02-22 ) |
下一个收益日期 | ( $-1.350 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.06 |
ATR14 | $0.0300 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Dube Michael P | Sell | 0 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 37 966 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 54 794 | Stock Option (right to buy) |
2024-03-01 | Basta James | Buy | 32 394 | Common Stock |
2024-03-04 | Basta James | Sell | 2 297 | Common Stock |
INSIDER POWER |
---|
85.54 |
Last 100 transactions |
Buy: 1 561 723 | Sell: 123 854 |
音量 相关性
Intellia Therapeutics Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Intellia Therapeutics Inc 相关性 - 货币/商品
Intellia Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $36.28M |
毛利润: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2023 |
营收: | $36.28M |
毛利润: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2022 |
营收: | $52.12M |
毛利润: | $44.55M (85.47 %) |
EPS: | $-6.37 |
FY | 2021 |
营收: | $33.05M |
毛利润: | $33.05M (100.00 %) |
EPS: | $-3.78 |
Financial Reports:
No articles found.
Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。